Thrombopoietin (Tpo), the ligand for the c-Mpl receptor, is a major regulator of megakaryopoiesis. Treatment of mice with Tpo raises the platelet count fourfold within a few days. Conversely, c-mpl knock-out mice have platelet counts that are 15% that of normal. The subunit structure of the c-Mpl receptor is not fully understood. Some cytokines that stimulate megakaryopoiesis (IL-6, IL-11, leukemia inhibitory factor, and oncostatin M) bind t o receptors that use gp130 as a signal transduction subunit. For these reasons, we determined whether gp130 function was required for Tpo-induced signal transduction. Murine marrow cells were cultured in semi-solid media in the presence of Tpo or IL-3, with or without a neutralizing anti-gpl30 monoclonal antibody (RX187) or a soluble form of c-Mpl receptor (soluble Mpl) that blocks Tpo bioactivity, and the numbers of colony-forming unit-megakaryocyte (CFU-Meg) colonies were counted on day 5. Murine marrow cells were also cultured in suspen-LATELET PRODUCTION is an orderly process in which committed megakaryocyte progenitor cells (colony-forming unit-megakaryocyte [CFU-Meg]) proliferate and differentiate into immature megakaryocytes, which then undergo cytoplasmic maturation and nuclear endoreduplication to generate mature, polyploid megakaryocytes. The mature megakaryocytes release platelets.',' These processes are governed by a flotilla of cytokines. Some of these hematopoietic growth factors (including IL-3 and stem cell factor [SCF]) predominantly affect CFU-Meg proliferation, while others (including IL-6, IL-1 l , leukemia inhibitory factor [LIF], and oncostatin M) mainly influence megakaryocyte maturation.'.' Thrombopoietin enhances both CFU-Meg growth and megakaryocyte Interleukin-6, IL-1 1, LIF, oncostatin M, and ciliary neurotropic factor have also been called neuropoietic cytokines,' I because of their diverse biological effects on hematopoiesis, B lymphocyte differentiation, induction of acute phase proteins, and survival and differentiation of neurons. The neuropoietic cytokines. together with cardiotrophin-I , l 2 use gpl30 as a component of the cell surface receptor complex.".'4 Ligand binding triggers association of gp 130, and formation of gp 130 homodimers or gp 130-LIF receptor heterodimers,
a signal transduction subunit. For these reasons, we determined whether gp130 function was required for Tpo-induced signal transduction. Murine marrow cells were cultured in semi-solid media in the presence of Tpo or IL-3, with or without a neutralizing anti-gpl30 monoclonal antibody (RX187) or a soluble form of c-Mpl receptor (soluble Mpl) that blocks Tpo bioactivity, and the numbers of colony-forming unit-megakaryocyte (CFU-Meg) colonies were counted on day 5. Murine marrow cells were also cultured in suspen-LATELET PRODUCTION is an orderly process in which committed megakaryocyte progenitor cells (colony-forming unit-megakaryocyte [CFU-Meg]) proliferate and differentiate into immature megakaryocytes, which then undergo cytoplasmic maturation and nuclear endoreduplication to generate mature, polyploid megakaryocytes. The mature megakaryocytes release platelets.',' These processes are governed by a flotilla of cytokines. Some of these hematopoietic growth factors (including IL-3 and stem cell factor [SCF]) predominantly affect CFU-Meg proliferation, while others (including IL-6, IL-1 l , leukemia inhibitory factor [LIF] , and oncostatin M) mainly influence megakaryocyte maturation.'.' Thrombopoietin enhances both CFU-Meg growth and megakaryocyte Interleukin-6, IL-1 1, LIF, oncostatin M, and ciliary neurotropic factor have also been called neuropoietic cytokines,' I because of their diverse biological effects on hematopoiesis, B lymphocyte differentiation, induction of acute phase proteins, and survival and differentiation of neurons. The neuropoietic cytokines. together with cardiotrophin-I , l 2 use gpl30 as a component of the cell surface receptor complex.". '4 Ligand binding triggers association of gp 130, and formation of gp 130 homodimers or gp 130-LIF receptor heterodimers, sion under serum-free conditions for 5 days, and megakaryocyte DNA content was measured by flow cytometry, as an index of nuclear maturation. The addition of RX187 did not block Tpo-induced CFU-Meg colony growth nor CFU-Meg nuclear maturation in suspension culture. However, IL-3-induced CFU-Meg colony growth and megakaryocyte nuclear maturation decreased in the presence of RX187. Soluble Mpl completely ablated Tpo-induced CFU-Meg growth, and partially blocked IL-3-stimulated CFU-Meg growth. Thus the effects of Tpo on megakaryopoiesis in vitro do not depend on cytokines that signal through gp130. Furthermore, it is unlikely that gp130 serves as a beta chain for the c-Mpl receptor, as Tpo signalling is unimpaired in the presence of RX187. In contrast, the effects of IL-3 on CFUMeg growth are mediated in part through Tpo and through gp130-signalling cytokines. 0 1996 b y The American Society of Hematology.
then initiation of signal transduction. Thus the gp130 receptor subunit, which is ubiquitously expressed in vivo,'5 plays a critical role in the transmission of signals of the IL-6 family of cytokines across the cell membrane.
Thrombopoietin, also known as Mpl ligand, megapoietin. or megakaryocyte growth and development factor, is a key regulator of megakaryopoiesis.'" In vitro, Tpo synergizes with erythropoietin, SCF, and IL-I 1 to promote growth of CFU-Meg colonies, and is a potent stimulant of megakaryocyte nuclear endoredupli~ation.~"'~~'~ Treatment of mice with Tpo increases the platelet count fourfold," while mice engineered to eliminate c-Mpl receptor expression exhibit platelet counts that are 15% that of normal levels.I9 Tpo is likely to be used clinically to speed platelet recovery after myelosuppressive chemotherapy, so an understanding of its mechanism of action is important.
The c-Mpl receptor is a member of the hematopoietic growth factor receptor as are the receptors for the IL-6 family of cytokines. Members of this receptor superfamily share structural features including conserved cysteine residues and a characteristic WSXWS motif in the extracellular domain, and an absence of recognizable kinase domains in the intracellular portion of the receptor. Certain of the receptors in the superfamily homodimerize after ligand binding: others require association of a signal transducing P chain, which may be shared by several members of the family. The subunit structure of the functional c-Mpl receptor complex has not been fully defined.
We investigated whether signal transduction via the gp 130 receptor subunit was required for CFU-Meg proliferation and megakaryocyte nuclear maturation in response to Tpo or to IL-3. Our results demonstrate that the effects of Tpo on megakaryopoiesis in vitro do not require gp130. Conversely, the effects of IL-3 on CFU-Meg proliferation irz r'itro are dependent in part on Tpo and on cytokines that signal through the gp 130 receptor subunit.
MATERIALS AND METHODS
Megakaryocyte colony assays. BhD2FI mice (Jackson Laboratories, Bar Harbor. ME), 8 units of Tpo or IL-3 activity were defined as that quantity that gave one-half maximal stimulation in the BaF3Mpl proliferation assay, or in the murine marrow CFU-GM colony assay, respectively." In some experiments, recombinant human IL-l1 (Genzyme, Boston, MA) was also used. A soluble form of c-Mpl receptor (soluble Mpl) was generated by truncation at the interface of the extracellular and transmembrane domains, was purified as previously de~cribed?~ and was provided by ZymoGenetics, Inc (Seattle, WA). Soluble Mpl is a specific competitive antagonist of Tpo a~tivity.'~ The RX187 rat antimouse monoclonal antibody (IgG2a) recognizes the extracellular domain of gp130, and neutralizes the bioactivity of IL-6 and IL-I I in vitro. To generate the M 1 8 7 antibody, a soluble form of the extracellular domain of murine gp130 was prepared by introducing a stop codon just above the transmembrane domain. Soluble gp130 was used to immunize a rat, and the resultant hybridomas were screened by flow cytometry for ability to recognize the native transmembrane form of murine gp130. The m 1 8 7 antibody was able to immunoprecipitate a 130 kD protein from '%- To determine if the horse serum used for the megakaryocyte colony assays contained Tpo, a Tpo-responsive murine cell line, DA-1-TpoZ6 was cultured in the presence of horse serum with or without soluble Mpl, and cell proliferation was quantitated. Parallel cultures of the DA-l-Tpo cells contained known quantities of Tpo. These experiments showed that the quantity of horse serum used for the CFU-Meg colony assays would contribute approximately 2 U/mL of Tpo activity to the culture. Megakaryocyte colony assays containing 15% horse serum but no added growth factor had no CFUMeg colonies, demonstrating that this quantity of Tpo alone was insufficient to support CFU-Meg colony growth.
Analysis of megakaryocyte ploidy. Murine marrow cells were cultured in serum-free suspension as previously d e s~r i b e d .~~'~~~~ Briefly, the marrow cells were cultured at a concentration of 1 X lo6 cells/mL in IMDM supplemented with 1% Nutridoma-SP (Boehringer Mannheim COT, Indianapolis, IN), 5 X m o m p mercaptoethanol, and growth factors with or without M 1 8 7 antibody as described above. The cells were incubated at 37°C for 5 days. The DNA content of the megakaryocytes was analyzed by flow cytometry after labeling with the 4A5 monoclonal antibody and with propidium iodide as previously des~ribed.~,~' The 4A5 monoclonal antibody recognizes a 74 kD glycoprotein present on murine megakaryocytes and and was generously provided by Dr Sam Burstein (University of Oklahoma, Oklahoma City, OK). Briefly, the cells were labeled with the 4A5 monoclonal antibody (15 &mL) or with control rat IgG2a antibody in 0.15 moVL NaCl (pH 7.4) containing 0.5% bovine serum albumin (Sigma) and 0.05% sodium azide (Sigma) for 30 minutes at 4"C, then incubated with FITC-conjugated Murine marrow cells were cultured in 0.285% agar in IMDM supplemented with 15% horse serum and 5 x mol/L p mercaptoethanol and Tpo (2,000 U/mL) or IL-3 (100 U/mL). The RX187 antibody was added at a concentration of 1.5 pg/mL, and soluble Mpl was added at a concentration of 5 pg/mL. The number of CFU-Meg-derived colonies was counted on day 5. The data are presented as the mean 2 SEM of triplicate plates. Five additional experiments gave similar results.
goat antirat IgG (Jackson Immunoresearch Labs, Inc, West Grove, PA) for 1 hour at 4°C. The cells were then incubated with propidium iodide (50 pg/mL; Molecular Probes, Inc. Eugene, OR) in a hypotonic citrate solution, and analyzed in a Coulter Epics Elite flow cytometer.'
RESULTS

Megakaryocytic colony growth.
We examined the ability of the neutralizing anti-gpl30 monoclonal antibody W 1 8 7 to block growth of CFU-Meg colonies in the presence of Tpo or IL-3 ( Table 1) . In seven independent experiments, the addition of RX187 antibody did not affect the number of CFU-Meg colonies found in the presence of 2,000 U/mL. of Tpo. In contrast to the results with Tpo, the addition of M 1 8 7 antibody blocked IL-3-stimulated CFU-Meg colony growth by approximately 40% to 45%. The addition of control IgG2a had no effect on CFU-Meg colony growth in the presence of Tpo or of IL-3 (data not shown). Soluble Mpl, which competes with cell surface c-Mpl for binding Tpo, completely inhibited Tpo-stimulated megakaryocyte colony growth, and inhibited XL-3-stimulated megakaryocyte colony growth by approximately 50% (Table 1) . The horse serum used in the CFU-Meg colony assay contributed approximately 2 U/mL of Tpo activity to the culture; this may account in part for the ability of soluble Mpl to inhibit CFUMeg colony growth in cultures containing IL-3.
To determine whether R X I 87 antibody would inhibit CFU-Meg colony growth in the presence of lower concentrations of Tpo, we cultured murine marrow cells with Tpo (0, 15, 60, 350, 1,OOO, or 2,000 U/mL) with or without RX187 antibody (Fig 1) . The addition of RX187 antibody did not block Tpo-induced CFU-Meg colony growth in the presence enhanced CFU-Meg colony growth (Fig 3) . The RX I87 antibody was able to ablate the incremental effect of IL-l 1 on growth of CFU-Meg colonies (Fig 3) . directly demonstrating the neutralizing activity of this antibody. Consistent with the data in Table 1 and Fig I , the RX187 antibody did not diminish CFU-Meg colony growth below that seen with Tpo alone.
To further define the neutralizing activity of RXI 87 antibody, murine marrow cells were cultured in the presence of a range of concentrations of IL-l I , with or without RX187 antibody or control IgG2a antibody (Fig 4) . The addition of RX I X7 antibody blocked the effects of IL-l1 on CFU-Meg colony growth. At high concentrations of IL-l I , a modest number of CFU-Meg colonies was found even in the presence of RX I87 antibody (Fig 4) . This suggests that IL-1 1 and RXI X7 antibody compete for binding to the gp130 subunit of of lower concentrations of Tpo (Fig l ) . The combination of Tpo plus IL-3 is a very potent stimulant of megakaryocytic colony growth (Fig 2) . The addition of RX 187 antibody did not diminish CFU-Meg colony growth in the presence of Tpo plus TL-3 (Fig 2) . suggesting that signal transduction via gp130 is not required for megakaryocytic colony growth under these conditions.
Although IL-l1 exerts its predominant effects on megakaryocyte maturation rather than on CFU-Meg proliferation, IL-l I can synergize with Tpo to augment the growth of megakaryocytic colonies. the receptor, and also demonstrates that the effects of m 1 8 7 antibody are not due to nonspecific toxicity. To ensure that appropriate concentrations of M 1 8 7 antibody were used for these experiments, an additional experiment examined the effects of varying amounts of the M 1 8 7 antibody on CFUMeg colony growth in the presence of Tpo plus IL-11 (Table  2 ). The RX187 antibody at a concentration of 0.5 to 1.5 pg/ mL completely blocked the incremental effect of IL-l1 on CFU-Meg colony growth. The control IgG2a antibody had no effect (Table 2) .
Megakulyocyte nuclear endoreduplication. We examined the DNA content of the megakaryocytes generated in serum-free suspension cultures in the presence of Tpo or IL-3, with or without RX187 antibody, to assess the effects of these cytokines on nuclear endoreduplication. Some megakaryocytes were produced even in the absence of exogenous growth factor, and the modal ploidy of these megakaryocytes was 16N (Fig 5) . When m 1 8 7 antibody was added to the cultures containing no exogenous growth factor, megakaryocyte ploidy decreased (data not shown), suggesting that endogenous production of cytokines that require gp130 as a signal transduction subunit is contributing to megakaryocyte endoreduplication in these cultures. IL-6 and IL-11, which are produced by stromal ~e l l s ,~~.~' are likely candidate cytokines; IL-6 can also be produced by megakaryocyte^.^',^^
The addition of Tpo profoundly increased megakaryocyte nuclear endoreduplication over that seen with no added growth factor (Fig 5) . In the presence of Tpo, the majority of megakaryocytes were of 32-64N ploidy (Fig 5) . The addition of RX187 did not diminish the proportion of 32N, 64N, and 128N megakaryocytes produced in the presence of Tpo (Fig 5) . A relatively small proportion of the megakaryocytes generated in the presence of IL-3 exhibited 32N, 64N, or 128N DNA content (Fig 6) , in contrast to megakaryocytes produced in the presence of Tpo. Neutralizing gp130 activity decreased megakaryocyte nuclear endoreduplication in the presence of IL-3, and virtually eliminated the production of 64N megakaryocytes (Fig 6) . We interpret these results to mean that the modest effect of IL-3 to stimulate megakaryocyte nuclear endoreduplication is dependent on the presence of endogenous IL-6 or IL-11 in these c u l t~r e s .~~-~* Murine marrow cells were cultured as described in Table 1 in the presence or absence of RX187 antibody (0.05 to 1.5 pg/mL). The data represent the mean 2 SEM of triplicate plates from one experiment. 
DISCUSSION
Hematopoiesis in vivo is intricately controlled to maintain the numbers of circulating erythrocytes, leukocytes, and platelets with a narrow range under normal circumstances. Much is understood about the physiology of the key growth factors that regulate the terminal stages of erythropoiesis and myelopoiesis, and several of these cytokines have been in clinical use for approximately 10 years. In contrast, the cytokine that predominantly controls megakaryopoiesis had remained elusive. The cloning of the c-mpl proto-~ncogene,~~ and the subsequent use of c-Mpl receptor affinity chromatography to isolate its ligand 34, 35 in parallel to a functional cloning strategy,36 and other purification appro ache^,^'.^' yielded Tpo. Contrary to predictions from experimental models of thrombocytopenia, and previous studies with partially purified molecules, recombinant Tpo was found to promote both the proliferation of CFU-Meg and the maturation of their progeny.
The network of hematopoietic cytokines is characterized by functional redundancy. Previous work had shown that IL-3 is a potent stimulant of murine CFU-Meg proliferation,"* and that the IL-6 family of cytokines including IL-6, IL-11, LIF, and oncostatin M stimulate megakaryocyte maturat i~n .~,~, ' Some of the members of the hematopoietic growth factor receptor superfamily share a common p chain, which plays a critical role in signal transduction.** In this study, we used a neutralizing anti-gpl30 monoclonal antibody to determine if gp130 was a component of the c-Mpl receptor complex, and to explore the extent to which the IL-6 family of cytokines contribute to Tpo-stimulated and to IL-3-stimulated megakaryopoiesis in vitro. Ablation of signal transduction through gp130 did not alter the ability of Tpo to stimulate the cytoplasmic maturation of rnegakary~cytes~~ or the proliferation of CFU-Meg or the nuclear endoreduplication of megakaryocytes. These results demonstrate that gp130 is not a component of the functional receptor complex for Tpo. Expression of a chimeric receptor consisting of the extracellular and transmembrane domains of the IL-4 receptor with the cytoplasmic domain of c-mpl BROUDY ET AL in a lymphoid cell line had shown that the cytoplasmic region of c-mpl is sufficient for signal transd~ction.~' Subsequent studies have dissected the regions of the c-mpl cytoplasmic domain that are required for activation of specific JAK and STAT protein~.~',~' However, because of the ubiquitous expression of gp13O,ls these studies do not rule out its participation in Tpo signal transduction. Furthermore, the present results with the anti-gp130 monoclonal antibody U 1 8 7 show that the activity of IL-11 is not required for the full spectrum of Tpo biological effects to be realized in vitro. These data confirm and extend a report that a polyclonal antibody to IL-11 did not impair the ability of Tpo to stimulate CFU-Meg growth."
In contrast to the results with Tpo, the effects of IL-3 on megakaryopoiesis do require the cooperation of cytokines that signal through the gp130 receptor subunit. A monoclonal antibody that neutralizes the effects of IL-6 blocked the ability of IL-3 to enhance murine megakaryop~iesis.~~ IL-3 can also induce megakaryocytes to produce IL-6," which can then stimulate megakaryocyte cytoplasmic maturation and nuclear endoreduplication via an autocrine loop mechanism. Studies with soluble Mpl have demonstrated that full megakaryocyte cytoplasmic maturation in the presence of IL-3 also requires TPO.'~ Taken together, the present results establish that the effects of Tpo on CFU-Meg colony growth and on megakaryocyte nuclear endoreduplication are not dependent on cytokines that signal through gp130, and it is unlikely that gpl30 serves as a p chain for the c-Mpl receptor complex. However, the effects of IL-3 on CFU-Meg proliferation and on megakaryocyte nuclear maturation are mediated in part by Tpo and by the IL-6 family of cytokines.
